Progressive fibrosing lung disease. Discussion aspects of the problem: A review

Cover Page

Cite item

Full Text

Abstract

The authors of the article prove the need to include a new name for the disease – "Progressive Fibrosing Lung Disease" into clinical practice. Recognition of the fact that some lung diseases end in a fibrosing process, which does not have any significant differences depending on the initial disease that led to fibrosis, will expand the indications for earlier prescription of antifibrotic drugs, which will undoubtedly improve the prognosis in this extremely severe category of patients.

About the authors

Mikhail M. Ilkovich

Pavlov First Saint Petersburg State Medical University

Email: mih.ilkovich@yandex.ru
ORCID iD: 0000-0001-5191-445X

д-р мед. наук, проф., дир. Научно-исследовательского института интерстициальных и орфанных заболеваний легких, зав. каф. пульмонологии фак-та последипломного образования

Russian Federation, Saint Petersburg

Lubov N. Novikova

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: novikoval06@mail.ru
ORCID iD: 0000-0001-9064-1554

канд. мед. наук, доц. каф. пульмонологии фак-та последипломного образования

Russian Federation, Saint Petersburg

Aleksandra A. Speranskaya

Pavlov First Saint Petersburg State Medical University

Email: a.spera@mail.ru
ORCID iD: 0000-0001-8322-4509

д-р мед. наук, проф., проф. каф. рентгенологии и радиационной медицины

Russian Federation, Saint Petersburg

Ivetta V. Dvorakovskaya

Pavlov First Saint Petersburg State Medical University

Email: i_dvorakovskaya@mail.ru
ORCID iD: 0000-0002-0333-751X

д-р мед. наук, вед. науч. сотр. отд. клинической и экспериментальной патологии органов дыхания

Russian Federation, Saint Petersburg

References

  1. Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология. 2015;25(5):600-12 [Avdeev SN. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25(5):600-12 (in Russian)]. doi: 10.18093/0869-0189-2015-25-5-600-612
  2. Liu GY, Budinger GRS, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. 2022;377:e066354. doi: 10.1136/bmj-2021-066354
  3. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. doi: 10.1164/rccm.202202-0399ST
  4. Илькович М.М., Новикова Л.Н. Идиопатические интерстициальные пневмонии. Терапевтический архив. 2021;93(3):333-6 [Ilkovich MM, Novikova LN. Idiopathic interstitial pneumonias. Terapevticheskii arkhiv (Ter. Arch.). 2021;93(3):333-6 (in Russian)]. doi: 10.26442/00403660.2021.03.200660
  5. Raghu G, Remy-Jardin M, Myers JL. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-68. doi: 10.1164/rccm.201807-1255ST
  6. Илькович М.М., Новикова Л.Н. Идиопатические интерстициальные пневмонии: объединительная концепция. Доктор.Ру. 2018;148(4):14-7 [Ilkovich MM, Novikova LN. Idiopathic interstitial pneumonias: a unifying concept. Doctor.Ru. 2018;148(4):14-7 (in Russian)].
  7. Диффузные паренхиматозные заболевания легких. Под ред. М.М. Ильковича. М.: ГЭОТАР-Медиа, 2021 [Diffuznye parenkhimatoznye zabolevaniia legkikh. Pod red. MM Il'kovicha. Moscow: GEOTAR-Media, 2021 (in Russian)].
  8. Авдеев С.Н., Гайнитдинова В.В., Мержоева З.М., и др. Обострение идиопатического легочного фиброза. Терапевтический архив. 2020;92(3):73-7 [Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, et al. Exacerbation of idiopathic pulmonary fibrosis. Terapevticheskii arkhiv (Ter. Arch.). 2020;92(3):73-7 (in Russian)]. doi: 10.26442/00403660.2020.03.000402
  9. Yanagihara T, Tsubouchi K, Gholiof M, at al. Connective-Tissue Growth Factor Contributes to TGF-β1-induced Lung Fibrosis. Am J Respir Cell Mol Biol. 2022;66(3):260-70. doi: 10.1165/rcmb.2020-0504OC

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies